Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Beta 3 Agonist Treatment in Heart Failure-2

NCT03926754 is registered in ClinicalTrials.gov with Henning Bundgaard as lead sponsor.

NCT NCT03926754
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03926754 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Beta 3 Agonist Treatment in Heart Failure-2
Lead sponsor
Henning Bundgaard
Phase
Phase 2/3
Overall status
Completed
Start date
January 23, 2017
Completion date
January 21, 2021
Enrollment
56 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

heart failure with reduced ejection fraction nyha class iii-iv